The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
The human gene ATP6V1H (UniProt accession Q9UI12) encodes the V-type proton ATPase subunit H, a regulatory component of the vacuolar H+-ATPase (V-ATPase) complex (wang2020structuresofa pages 3-5, forgac1999structureandproperties pages 1-2). V-ATPases are ATP-driven proton pumps that acidify intracellular compartments and, in specialized cell types, export protons across the plasma membrane (forgac1999structureandproperties pages 1-2, eaton2021theh+atpase(vatpase) pages 1-5). The ATP6V1H protein belongs to the V-ATPase H subunit family and contains conserved V-ATPase_H_N and V-ATPase_H_C domains, consistent with its structural role in the enzyme complex.
V-ATPases are large multisubunit complexes (~830 kDa) composed of two functional domains: the cytosolic V1 domain responsible for ATP hydrolysis, and the membrane-embedded V0 domain that translocates protons (wang2020structuresofa pages 1-3, forgac1999structureandproperties pages 1-2, eaton2021theh+atpase(vatpase) pages 1-5). The human V1 complex contains eight different subunits (A, B, C, D, E, F, G, and H), while the V0 complex comprises subunits a, c, c′, c″, d, e, ATP6AP1, and ATP6AP2 (wang2020structuresofa pages 3-5, chen2024vatpaseincancer pages 1-3).
ATP6V1H is a single-copy V1 subunit located at the V1-V0 interface, where it forms part of a collar structure together with subunit C and the N-terminal domain of subunit a from the V0 complex (wang2020structuresofa pages 1-3, wang2020structuresofa pages 3-5). High-resolution cryo-electron microscopy structures of human V-ATPase at 2.9-3.1 Å resolution reveal that subunit H interacts extensively with peripheral stalk 1 (composed of subunits E and G) and the a-subunit N-terminal domain, bridging the V1 and V0 sectors (wang2020structuresofa pages 3-5).
| Feature | ATP6V1H / subunit H summary | Evidence |
|---|---|---|
| Gene/protein identity | Human ATP6V1H encodes V-type proton ATPase subunit H, a component of the V1 cytosolic sector of the V-ATPase complex, consistent with the V1 A–H subunit organization described for eukaryotic V-ATPases. | (forgac1999structureandproperties pages 1-2, eaton2021theh+atpase(vatpase) pages 1-5, toei2010regulationandisoform pages 1-2) |
| Location within V-ATPase | Subunit H is part of the peripheral/cytosolic V1 domain, not the membrane-embedded V0 proton-translocating domain. In the human cryo-EM structure, H contributes to the bottom collar together with subunit C and the N-terminal domain of subunit a from V0, placing it at the V1–V0 interface. | (wang2020structuresofa pages 3-5, forgac1999structureandproperties pages 1-2, eaton2021theh+atpase(vatpase) pages 1-5, toei2010regulationandisoform pages 1-2) |
| Stoichiometry | The V1 sector contains one copy of subunit H per holoenzyme; human V-ATPase structures identify one H together with single copies of C, D, F and three copies each of A, B2, E1 and G1. | (wang2020structuresofa pages 3-5, forgac1999structureandproperties pages 1-2) |
| Primary biochemical role | ATP6V1H is not the catalytic ATP-hydrolyzing subunit; ATP hydrolysis occurs at A/B interfaces in V1. Instead, subunit H has a structural/regulatory coupling role, helping connect ATP hydrolysis in V1 to proton pumping in V0. Overall enzyme reaction: ATP + H2O powers proton translocation across endomembrane or plasma membranes. | (forgac1999structureandproperties pages 1-2, eaton2021theh+atpase(vatpase) pages 1-5, jefferies2008functionstructureand pages 1-2, toei2010regulationandisoform pages 1-2) |
| Molecular function in coupling | Structural analysis indicates that subunit H interacts across V1 and V0-linked scaffolding elements and may explain the ability of H to couple V1 ATPase activity to V0 proton pumping activity in the intact enzyme. | (wang2020structuresofa pages 3-5, wang2020structuresofa pages 5-7) |
| Protein interactions | In the human V-ATPase structure, subunit H interacts extensively with peripheral stalk 1 (PS-1; E/G stalk) and the N-terminal domain of subunit a (a-NTD). These contacts bridge the V1 and V0 sectors and help stabilize the collar region. | (wang2020structuresofa pages 3-5) |
| Structural context | H is positioned in the collar/scaffold region rather than the rotary ATPase head or proton pore. This location is consistent with a role in holding the stator architecture together while the central stalk and c-ring rotate during catalysis. | (wang2020structuresofa pages 3-5, wang2020structuresofa pages 5-7, eaton2021theh+atpase(vatpase) pages 1-5) |
| Role in rotational states | Presence of subunit H in the human structure correlates with stabilization of rotational state 1 relative to other states, suggesting an influence on conformational equilibrium and enzyme mechanics. | (wang2020structuresofa pages 3-5) |
| Role in regulation | V-ATPase activity can be regulated by reversible V1–V0 disassembly/reassembly. Because H is a V1 subunit located at the V1–V0 interface, its position is consistent with participation in this regulatory architecture; separated V1 and V0 sectors are inactive, preventing futile ATP hydrolysis or proton leak. | (eaton2021theh+atpase(vatpase) pages 1-5, eaton2021theh+atpase(vatpase) pages 5-9) |
| Role in assembly | Human structural work identifies H as an essential resolved component of the assembled human holoenzyme and highlights its cross-complex contacts, supporting a role in stabilizing assembled V-ATPase rather than forming the membrane pore or catalytic nucleotide-binding sites directly. | (wang2020structuresofa pages 3-5, wang2020structuresofa pages 5-7) |
| Cellular functional consequences | Through its role in V-ATPase integrity and coupling, ATP6V1H contributes indirectly to organelle acidification, including acidification of endosomes, lysosomes, Golgi-related compartments, and secretory vesicles, and in specialized cells to plasma membrane proton secretion. | (forgac1999structureandproperties pages 1-2, eaton2021theh+atpase(vatpase) pages 1-5, jefferies2008functionstructureand pages 1-2, toei2010regulationandisoform pages 1-2) |
Table: This table summarizes where ATP6V1H sits in the V-ATPase complex, how many copies are present, and what structural and regulatory roles subunit H plays. It is useful for distinguishing ATP6V1H from catalytic and membrane proton-translocating subunits while highlighting its coupling and scaffold functions.
While ATP hydrolysis occurs at the interface between the A and B subunits in the V1 head domain, subunit H plays a critical coupling role that connects ATP hydrolysis in V1 to proton pumping through V0 (wang2020structuresofa pages 3-5, wang2020structuresofa pages 5-7). The V-ATPase operates through a rotary mechanism: ATP hydrolysis drives conformational changes in the A3B3 hexamer, causing rotation of the central stalk (subunits D and F) and the associated c-ring in V0, which translocates protons across the membrane (wang2020structuresofa pages 1-3, forgac1999structureandproperties pages 1-2).
Subunit H stabilizes the assembled holoenzyme and influences the conformational equilibrium between rotational states. Structural analysis indicates that the presence of subunit H correlates with stabilization of rotational state 1 relative to states 2 and 3, suggesting it modulates enzyme mechanics during the catalytic cycle (wang2020structuresofa pages 3-5, wang2020structuresofa pages 5-7). The extensive interactions of H across V1 and V0 components explain its ability to couple V1's ATPase activity to V0's proton-pumping activity in the intact enzyme (wang2020structuresofa pages 3-5).
The V-ATPase complex uses ATP as its substrate, hydrolyzing it to ADP and inorganic phosphate to power proton transport. The overall reaction is:
ATP + H2O + H+cytoplasm → ADP + Pi + H+lumen/extracellular
This reaction establishes both a pH gradient and membrane potential across the targeted membrane (forgac1999structureandproperties pages 1-2, jefferies2008functionstructureand pages 1-2, toei2010regulationandisoform pages 1-2).
ATP6V1H-containing V-ATPase complexes localize to multiple intracellular compartments where they maintain organellar pH homeostasis (forgac1999structureandproperties pages 1-2, eaton2021theh+atpase(vatpase) pages 1-5, jefferies2008functionstructureand pages 1-2, toei2010regulationandisoform pages 1-2):
Lysosomes: V-ATPases maintain the acidic lysosomal lumen (pH 4.5-5.0) required for the activity of degradative hydrolases, supporting protein degradation, autophagy, and metabolic recycling (eaton2021theh+atpase(vatpase) pages 1-5, jefferies2008functionstructureand pages 1-2, toei2010regulationandisoform pages 1-2).
Endosomes: Acidification of early and late endosomes facilitates receptor-ligand dissociation, receptor recycling, endocytic trafficking, and formation of endosomal carrier vesicles (forgac1999structureandproperties pages 1-2, jefferies2008functionstructureand pages 1-2, toei2010regulationandisoform pages 1-2). Endosomal acidification is also required for pH-dependent viral entry, including influenza and other envelope viruses (forgac1999structureandproperties pages 1-2, jefferies2008functionstructureand pages 1-2).
Golgi and Secretory Vesicles: V-ATPases generate luminal acidity within the Golgi and secretory compartments, supporting protein sorting, prohormone processing (e.g., insulin maturation), and vesicle maturation (forgac1999structureandproperties pages 1-2, jefferies2008functionstructureand pages 1-2, toei2010regulationandisoform pages 1-2).
Synaptic Vesicles: In neuronal cells, the proton gradient produced by V-ATPases provides the driving force for neurotransmitter uptake into synaptic vesicles via coupled transporters (forgac1999structureandproperties pages 1-2, jefferies2008functionstructureand pages 1-2, toei2010regulationandisoform pages 1-2).
In certain differentiated cell types, V-ATPases are targeted to the plasma membrane for extracellular acidification (forgac1999structureandproperties pages 1-2, eaton2021theh+atpase(vatpase) pages 1-5, toei2010regulationandisoform pages 1-2):
Osteoclasts: V-ATPases at the ruffled border of osteoclasts secrete protons to acidify the resorption lacuna, dissolving bone mineral matrix during bone remodeling (eaton2021theh+atpase(vatpase) pages 1-5, duan2018vatpasesandosteoclasts pages 1-2, toei2010regulationandisoform pages 1-2).
Renal Intercalated Cells: Plasma membrane V-ATPases in kidney intercalated cells secrete acid into urine, maintaining systemic acid-base balance (forgac1999structureandproperties pages 1-2, eaton2021theh+atpase(vatpase) pages 1-5, toei2010regulationandisoform pages 1-2).
Epididymal Clear Cells: V-ATPases acidify luminal fluid in the male reproductive tract, creating the low pH environment necessary for sperm maturation and storage (eaton2021theh+atpase(vatpase) pages 1-5, toei2010regulationandisoform pages 1-2).
Tumor Cells: Some invasive cancers relocalize V-ATPases to the plasma membrane, acidifying the extracellular tumor microenvironment while maintaining an alkaline cytosol, which supports tumor invasion and metastasis (eaton2021theh+atpase(vatpase) pages 1-5, chen2024vatpaseincancer pages 1-3).
| Localization category | Specific compartment / cell type | ATP6V1H-containing V-ATPase role | Biological processes supported | Recent disease/pathway findings (2023-2025) |
|---|---|---|---|---|
| Intracellular endomembrane system | Early and late endosomes | ATP-driven proton pumping acidifies endosomal lumen; ATP6V1H is part of the V1 sector that couples ATP hydrolysis to proton transport by the holoenzyme | Receptor-ligand dissociation, receptor recycling, endocytic trafficking, endosomal carrier vesicle formation, entry of pH-dependent viruses and toxins (forgac1999structureandproperties pages 1-2, jefferies2008functionstructureand pages 1-2, toei2010regulationandisoform pages 1-2) | V-ATPase remains integrated with nutrient- and stress-signaling networks, including lysosome-linked mTORC1/AMPK control discussed in recent reviews and pathway studies (chen2024vatpaseincancer pages 1-3, duque2025atg16l1controlsmammalian pages 1-3) |
| Intracellular degradative organelles | Lysosomes | Maintains acidic lysosomal lumen required for hydrolase activity; assembled V-ATPase supports organelle acidification and proteolysis (eaton2021theh+atpase(vatpase) pages 1-5, jefferies2008functionstructureand pages 1-2, toei2010regulationandisoform pages 1-2) | Protein degradation, autophagic cargo turnover, metabolite recycling, lysosomal homeostasis (eaton2021theh+atpase(vatpase) pages 1-5, jefferies2008functionstructureand pages 1-2, eaton2021theh+atpase(vatpase) pages 5-9) | TFEB-responsive regulation of Atp6v1h was shown to be necessary for lysosomal acidification and microglial activation in tauopathy; disrupting the CLEAR element in Atp6v1h impaired lysosomal function and altered mTOR/HIF-1-related microglial states (wang2024tfeb–vacuolaratpasesignaling pages 1-7). ATG16L1 was also shown to regulate mammalian V-ATPase assembly/activity and endolysosomal acidification (duque2025atg16l1controlsmammalian pages 1-3) |
| Secretory and biosynthetic pathway | Golgi-derived vesicles / secretory vesicles | Generates luminal acidity within biosynthetic and secretory compartments (forgac1999structureandproperties pages 1-2, toei2010regulationandisoform pages 1-2) | Protein sorting, prohormone/zymogen processing, vesicle loading and maturation (forgac1999structureandproperties pages 1-2, jefferies2008functionstructureand pages 1-2, toei2010regulationandisoform pages 1-2) | Recent literature emphasizes that altered V-ATPase regulation can broadly reshape intracellular pH homeostasis and trafficking in disease states, especially cancer (chen2024vatpaseincancer pages 1-3) |
| Neurosecretory compartments | Synaptic vesicles and related secretory granules | Proton gradient produced by V-ATPase energizes uptake systems for neurotransmitters and other small molecules (forgac1999structureandproperties pages 1-2, jefferies2008functionstructureand pages 1-2) | Neurotransmitter loading and release competence of synaptic vesicles; secretory granule function (forgac1999structureandproperties pages 1-2, jefferies2008functionstructureand pages 1-2) | Brain/tauopathy studies highlight ATP6V1H as a TFEB-regulated lysosomal gene with consequences for neuroimmune responses and neurodegeneration-related lysosome biology (wang2024tfeb–vacuolaratpasesignaling pages 1-7) |
| Specialized plasma membrane localization | Osteoclast ruffled border / plasma membrane | Exports protons extracellularly to acidify the resorption lacuna; ATP6V1H contributes as a V1 regulatory/coupling subunit in osteoclast V-ATPase complexes (eaton2021theh+atpase(vatpase) pages 1-5, duan2018vatpasesandosteoclasts pages 1-2, toei2010regulationandisoform pages 1-2) | Bone matrix dissolution, bone resorption, bone remodeling (duan2018vatpasesandosteoclasts pages 1-2, toei2010regulationandisoform pages 1-2) | ATP6V1H has been linked to osteoporosis-related phenotypes. A 2024 mouse study reported that Atp6v1h deficiency modulated bone loss under simulated microgravity through Fos-Jun-Src-Integrin pathway changes, reinforcing its relevance to osteoclast biology and osteoporosis mechanisms (zhao2024atp6v1hdeficiencyblocks pages 1-2) |
| Specialized plasma membrane localization | Renal intercalated cells (kidney) | Plasma membrane V-ATPase secretes protons into urine to maintain systemic acid-base balance (forgac1999structureandproperties pages 1-2, eaton2021theh+atpase(vatpase) pages 1-5, toei2010regulationandisoform pages 1-2) | Urinary acidification and renal pH homeostasis (forgac1999structureandproperties pages 1-2, toei2010regulationandisoform pages 1-2) | Although ATP6V1H-specific human renal disease evidence is limited here, V-ATPase dysfunction more broadly is central to acidification defects and is a key framework for understanding V-ATPase-linked renal physiology/pathophysiology (eaton2021theh+atpase(vatpase) pages 1-5, toei2010regulationandisoform pages 1-2) |
| Specialized plasma membrane localization | Epididymal clear cells / male reproductive tract | Extracellular proton secretion acidifies luminal fluid (eaton2021theh+atpase(vatpase) pages 1-5, toei2010regulationandisoform pages 1-2) | Sperm maturation and storage in an acidic environment (eaton2021theh+atpase(vatpase) pages 1-5, toei2010regulationandisoform pages 1-2) | Recent reviews continue to cite plasma membrane V-ATPases as crucial examples of tissue-specialized acidification machinery, though ATP6V1H-specific new reproductive findings were not prominent in the retrieved set (eaton2021theh+atpase(vatpase) pages 1-5, chen2024vatpaseincancer pages 1-3) |
| Specialized plasma membrane localization | Tumor cell plasma membrane / invasive cancer cells | Some cancers relocalize/enhance V-ATPase at the plasma membrane to acidify the extracellular milieu while helping maintain alkaline cytosol (eaton2021theh+atpase(vatpase) pages 1-5, chen2024vatpaseincancer pages 1-3) | Tumor invasion, metastasis, drug resistance, adaptation to acidic tumor microenvironment (eaton2021theh+atpase(vatpase) pages 1-5, chen2024vatpaseincancer pages 1-3) | A 2024 review highlighted V-ATPase as a therapeutic target in cancer, linking its activity to proliferation, metastasis, mTORC1/AMPK signaling, non-canonical autophagy, and treatment resistance (chen2024vatpaseincancer pages 1-3) |
| Immune / CNS lysosome-related compartments | Microglia and endolysosomal immune compartments | Supports lysosomal acidification required for immune-cell degradative and signaling responses (eaton2021theh+atpase(vatpase) pages 1-5, wang2024tfeb–vacuolaratpasesignaling pages 1-7) | Lysosome-dependent immune activation, degradation programs, stress adaptation (wang2024tfeb–vacuolaratpasesignaling pages 1-7, duque2025atg16l1controlsmammalian pages 1-3) | In tauopathy, TFEB-v-ATPase signaling through Atp6v1h regulated lysosomal function and microglial activation; impaired Atp6v1h transcription blunted microglial response while worsening tau pathology (wang2024tfeb–vacuolaratpasesignaling pages 1-7) |
| Dynamic assembly state rather than fixed compartment | Cytosolic V1 pool associating with endomembranes | ATP6V1H resides in V1, which can reversibly dissociate from and reassemble with membrane V0 sectors; this tunes local proton-pumping activity (eaton2021theh+atpase(vatpase) pages 5-9, duque2025atg16l1controlsmammalian pages 1-3) | Regulation of organelle pH, energy conservation, adaptive control of lysosomal/endosomal acidification (eaton2021theh+atpase(vatpase) pages 5-9, duque2025atg16l1controlsmammalian pages 1-3) | Recent mechanistic work shows mammalian V-ATPase activity is controlled by factors such as ATG16L1 and assembly regulators, linking ATP6V1H-containing V1 to autophagy-associated and nutrient-sensing pathways (duque2025atg16l1controlsmammalian pages 1-3) |
Table: This table summarizes where ATP6V1H-containing V-ATPase complexes function in human cells and what biological processes they support. It also highlights recent 2023-2025 findings linking these localizations to lysosomal signaling, osteoporosis, neurodegeneration, autophagy, and cancer.
ATP6V1H-containing V-ATPases are essential for lysosomal acidification and autophagy, processes central to cellular homeostasis (eaton2021theh+atpase(vatpase) pages 1-5, jefferies2008functionstructureand pages 1-2, toei2010regulationandisoform pages 1-2). Lysosomal acidification enables the activity of acid hydrolases for degradation of proteins, organelles, and other cellular cargo delivered via macroautophagy and other autophagy pathways (eaton2021theh+atpase(vatpase) pages 1-5, jefferies2008functionstructureand pages 1-2).
V-ATPase functions as a critical component of the lysosomal nutrient-sensing machinery that regulates mechanistic target of rapamycin complex 1 (mTORC1) (eaton2021theh+atpase(vatpase) pages 1-5, chen2024vatpaseincancer pages 1-3). mTORC1 is a master regulator of cellular anabolism and growth that senses amino acid availability at the lysosomal surface. Recent studies demonstrate that mTORC1 activity directly controls V-ATPase assembly and lysosomal acidification: when mTORC1 is active (nutrients abundant), V1 domains including ATP6V1H remain predominantly cytosolic, limiting lysosomal acidification and catabolic activity; when mTORC1 declines (nutrient limitation), V1 assembles with V0 on lysosomes to form active pumps, increasing acidification and protein degradation (chen2024vatpaseincancer pages 1-3).
V-ATPase participates in lysosome-centered energy sensing networks that coordinate with AMP-activated protein kinase (AMPK), a key cellular energy sensor (eaton2021theh+atpase(vatpase) pages 1-5, chen2024vatpaseincancer pages 1-3). The lysosomal surface integrates nutrient and energy cues through V-ATPase interactions with both mTORC1 and AMPK, coordinating catabolic versus anabolic programs in response to metabolic stress (chen2024vatpaseincancer pages 1-3).
ATP6V1H itself is transcriptionally regulated by transcription factor EB (TFEB), a master regulator of lysosomal biogenesis and autophagy (wang2024tfeb–vacuolaratpasesignaling pages 1-7). TFEB binds to Coordinated Lysosomal Expression and Regulation (CLEAR) motifs in the promoters of lysosomal genes, including Atp6v1h. A 2024 study in a mouse tauopathy model demonstrated that mutating the CLEAR sequence in the Atp6v1h promoter impaired TFEB-dependent transcriptional induction, resulting in reduced lysosomal acidification, impaired microglial activation, and increased tau pathology (wang2024tfeb–vacuolaratpasesignaling pages 1-7). This work established ATP6V1H as a critical TFEB-responsive node linking transcriptional lysosome programs to functional lysosomal acidification capacity.
Recent mechanistic studies in 2025 revealed that ATG16L1, a protein primarily known for its role in autophagy, directly binds and regulates V-ATPase activity (duque2025atg16l1controlsmammalian pages 1-3). ATG16L1 knockout elevated V-ATPase activity, increased V1 domain presence on endomembranes, and increased the number of acidified intracellular compartments, indicating that ATG16L1 normally restrains V-ATPase assembly and activity (duque2025atg16l1controlsmammalian pages 1-3). ATG16L1's ability to efficiently bind V-ATPase (including the V1 domain containing ATP6V1H) is required for its inhibitory role in endolysosomal acidification and for control of Mycobacterium tuberculosis infection (duque2025atg16l1controlsmammalian pages 1-3). This expands the ATG16L1-V-ATPase relationship beyond simple recruitment to direct functional control of proton pump activity.
V1 domain assembly onto lysosomal V0 is regulated by assembly factors related to the yeast RAVE (Regulator of ATPase of Vacuoles and Endosomes) complex (eaton2021theh+atpase(vatpase) pages 5-9, lee2025dmxl1promotesrecruitment pages 1-2). In 2025, DMXL1 (the mammalian ortholog of yeast Rav1) was identified as a key regulator that assembles with ROGDI and WDR7 and associates with both V0 and V1 subunits (lee2025dmxl1promotesrecruitment pages 1-2). TRPML1 channel activation triggers DMXL1/DMXL2-dependent recruitment of V1 (containing ATP6V1H) to lysosomes, promoting V-ATPase assembly, lumenal acidification, and hydrolytic capacity (lee2025dmxl1promotesrecruitment pages 1-2). This work revealed mammalian assembly-control mechanisms for lysosomal V-ATPase recruitment during stress-responsive remodeling.
A unique regulatory mechanism for V-ATPase is reversible disassembly, wherein the V1 and V0 domains dissociate in response to environmental signals such as glucose deprivation (eaton2021theh+atpase(vatpase) pages 1-5, eaton2021theh+atpase(vatpase) pages 5-9). When dissociated, both V1 and V0 are inactive: V1 lacks ATPase activity without V0, and V0 does not conduct protons without V1, preventing futile ATP hydrolysis and proton leak (eaton2021theh+atpase(vatpase) pages 5-9). ATP6V1H, as a V1 subunit positioned at the V1-V0 interface in the collar region, participates in this reversible assembly architecture (wang2020structuresofa pages 3-5, eaton2021theh+atpase(vatpase) pages 5-9). Assembly and disassembly regulate V-ATPase activity in mammalian cells during the lysosome regeneration cycle, aging, and metabolic adaptation (eaton2021theh+atpase(vatpase) pages 5-9).
| Pathway / regulatory mechanism | Role of ATP6V1H-containing V-ATPase | Mechanistic summary | Key recent findings (2022-2025) | Evidence |
|---|---|---|---|---|
| mTORC1 nutrient sensing | V-ATPase acts as a lysosomal platform and activity switch that helps determine lysosomal acidification status and thereby regulates mTORC1-dependent catabolic versus anabolic states | When nutrients are sufficient, mTORC1 activity suppresses V1 recruitment/assembly on lysosomes, limiting acidification and catabolic activity; when mTORC1 declines, V1 domains assemble with V0 on lysosomes to form active pumps, lowering lysosomal pH and increasing degradation. V-ATPase is also described as part of the lysosomal nutrient-sensing machinery that communicates amino acid status to mTORC1 (eaton2021theh+atpase(vatpase) pages 1-5, chen2024vatpaseincancer pages 1-3) | Direct control of lysosomal catabolism by mTORC1 through V-ATPase assembly was shown in 2022, establishing that mTORC1 can rapidly regulate lysosomal acidification by controlling V1-V0 assembly. Recent reviews in 2024 continue to place V-ATPase at the center of lysosomal mTORC1 signaling in cancer and metabolism (chen2024vatpaseincancer pages 1-3) | (eaton2021theh+atpase(vatpase) pages 1-5, chen2024vatpaseincancer pages 1-3) |
| AMPK energy sensing | V-ATPase participates in lysosome-centered nutrient/energy sensing networks that coordinate with AMPK | Reviews of V-ATPase signaling note that the lysosomal surface integrates nutrient cues through V-ATPase with AMPK and mTORC1. In stress or nutrient limitation states, V-ATPase-dependent acidification and assembly state influence the signaling environment that supports AMPK-linked catabolic adaptation (eaton2021theh+atpase(vatpase) pages 1-5, chen2024vatpaseincancer pages 1-3) | Recent pathway-focused reviews from 2024 emphasize V-ATPase interactions with AMPK as part of the metabolic regulatory machinery in cancer and other disease settings, although ATP6V1H-specific biochemical steps remain less directly resolved than for TFEB or ATG16L1 (chen2024vatpaseincancer pages 1-3) | (eaton2021theh+atpase(vatpase) pages 1-5, chen2024vatpaseincancer pages 1-3) |
| TFEB transcriptional regulation | ATP6V1H itself is TFEB-responsive, linking transcriptional lysosome programs to V-ATPase abundance and lysosomal competence | TFEB binds CLEAR-regulated lysosomal gene programs. In a 2024 tauopathy study, mutating the CLEAR sequence of Atp6v1h reduced the TFEB response, impairing lysosomal acidification and lysosomal activity. This demonstrates that ATP6V1H is not only a structural V-ATPase component but also a transcriptionally regulated node in lysosomal adaptation (wang2024tfeb–vacuolaratpasesignaling pages 1-7) | In 2024, endogenous disruption of TFEB-dependent Atp6v1h regulation in mice impaired lysosomal function, reduced microglial activation, and increased tau pathology, providing unusually direct in vivo evidence for ATP6V1H in TFEB-lysosome signaling (wang2024tfeb–vacuolaratpasesignaling pages 1-7) | (wang2024tfeb–vacuolaratpasesignaling pages 1-7) |
| Autophagy and lysosomal homeostasis | ATP6V1H-containing V-ATPase is required for lysosomal acidification that underpins autophagic degradation and broader lysosomal homeostasis | V-ATPase acidifies lysosomes, enabling hydrolase activity, cargo degradation, and autophagic flux. Disrupting ATP6V1H-dependent V-ATPase regulation impairs lysosomal function. Reviews also describe V-ATPase as a signaling hub, not merely a proton pump, in endolysosomal and autophagic pathways (eaton2021theh+atpase(vatpase) pages 1-5, jefferies2008functionstructureand pages 1-2, toei2010regulationandisoform pages 1-2) | The 2024 TFEB-Atp6v1h study tied altered ATP6V1H expression to defective lysosomal acidification in vivo. Recent reviews and mechanistic studies likewise emphasize lysosomal homeostasis as a central disease-relevant output of V-ATPase regulation (chen2024vatpaseincancer pages 1-3, wang2024tfeb–vacuolaratpasesignaling pages 1-7) | (eaton2021theh+atpase(vatpase) pages 1-5, chen2024vatpaseincancer pages 1-3, jefferies2008functionstructureand pages 1-2, toei2010regulationandisoform pages 1-2, wang2024tfeb–vacuolaratpasesignaling pages 1-7) |
| ATG16L1 interaction axis | ATG16L1 binds V-ATPase and regulates its activity; ATP6V1H-containing V1 is part of the regulated assembly state | ATG16L1, best known from autophagy, directly interfaces with V-ATPase. ATG16L1 knockout increases V-ATPase activity, increases V1 presence on endomembranes, and increases acidified compartments, indicating that ATG16L1 normally restrains V-ATPase assembly/activity in mammalian cells (duque2025atg16l1controlsmammalian pages 1-3) | A 2025 study showed that ATG16L1 controls mammalian V-ATPase and endolysosomal acidification, expanding the ATG16L1-V-ATPase relationship beyond recruitment during noncanonical autophagy to direct control of proton pump function (duque2025atg16l1controlsmammalian pages 1-3) | (duque2025atg16l1controlsmammalian pages 1-3) |
| DMXL1 / assembly-factor regulation | ATP6V1H-containing V1 assembly on lysosomes is regulated by DMXL1/DMXL2-containing machinery related to yeast RAVE | DMXL1 assembles with ROGDI and WDR7 and associates with V0 and V1 subunits. Upon TRPML1 activation, DMXL1/DMXL2 promote recruitment of V1 to lysosomes, supporting V-ATPase assembly, lumen acidification, and hydrolytic capacity (lee2025dmxl1promotesrecruitment pages 1-2) | The 2025 DMXL1 study identified a mammalian assembly-control module for lysosomal V-ATPase recruitment, helping explain how V1-containing complexes, including ATP6V1H, are dynamically targeted to lysosomes during stress-responsive remodeling (lee2025dmxl1promotesrecruitment pages 1-2) | (lee2025dmxl1promotesrecruitment pages 1-2) |
| Reversible V1-V0 assembly/disassembly | ATP6V1H, as a V1 subunit at the V1-V0 interface, participates in the reversible assembly architecture that controls pump activation | V-ATPase activity is regulated by reversible dissociation of cytosolic V1 from membrane V0. Separated sectors are inactive, preventing futile ATP hydrolysis or proton leak. Subunit H sits in the collar/interface region and helps couple V1 ATPase activity to V0 proton pumping in assembled holoenzyme, making it structurally relevant to assembly-dependent regulation (wang2020structuresofa pages 3-5, eaton2021theh+atpase(vatpase) pages 5-9) | Recent mammalian studies and reviews continue to show that assembly/disassembly is a major control point for lysosomal pH regulation. Structural work on human V-ATPase highlights subunit H as part of the interdomain coupling apparatus that stabilizes the assembled state (wang2020structuresofa pages 3-5, wang2020structuresofa pages 5-7, eaton2021theh+atpase(vatpase) pages 5-9) | (wang2020structuresofa pages 3-5, wang2020structuresofa pages 5-7, eaton2021theh+atpase(vatpase) pages 5-9) |
| Disease-linked signaling outputs | ATP6V1H-dependent V-ATPase regulation feeds into neurodegeneration, cancer, bone biology, and metabolic disease pathways | Because V-ATPase controls lysosomal pH, nutrient signaling, and autophagy, perturbation of ATP6V1H can affect microglial state, tumor adaptation, osteoclast activity, and diabetes-associated expression programs. ATP6V1H has been implicated in bone homeostasis and in altered expression associated with type 2 diabetes (zhao2024atp6v1hdeficiencyblocks pages 1-2, molina2011decreasedexpressionof pages 1-3) | 2024 work connected Atp6v1h to osteoclast-linked bone loss pathways under simulated microgravity, while 2024 cancer review literature emphasized V-ATPase as a therapeutic target in tumor metabolism, invasion, and drug resistance. Earlier human expression work also reported reduced ATP6V1H expression with diabetes progression (chen2024vatpaseincancer pages 1-3, zhao2024atp6v1hdeficiencyblocks pages 1-2, molina2011decreasedexpressionof pages 1-3) | (chen2024vatpaseincancer pages 1-3, zhao2024atp6v1hdeficiencyblocks pages 1-2, molina2011decreasedexpressionof pages 1-3) |
Table: This table summarizes the main signaling pathways and regulatory mechanisms involving ATP6V1H-containing V-ATPase complexes, emphasizing lysosomal nutrient sensing, transcriptional control, autophagy, and dynamic assembly regulation. It is useful for linking ATP6V1H’s structural role in the proton pump to current disease-relevant pathway biology.
A 2024 comprehensive review highlighted V-ATPase as a critical player in cancer cell biology and a promising therapeutic target (chen2024vatpaseincancer pages 1-3). Enhanced V-ATPase activity in cancer cells is closely associated with tumor cell proliferation, metastasis, and adaptation to the acidic tumor microenvironment (chen2024vatpaseincancer pages 1-3). V-ATPase promotes tumor invasion by regulating extracellular pH and supports drug resistance through its interactions with mTORC1, AMPK, and non-canonical autophagy pathways (chen2024vatpaseincancer pages 1-3). Multiple V-ATPase inhibitors are being evaluated as potential anticancer agents.
The 2024 study by Wang and colleagues demonstrated that TFEB-dependent regulation of Atp6v1h is essential for lysosomal function and microglial activation in Alzheimer's disease-related tauopathy (wang2024tfeb–vacuolaratpasesignaling pages 1-7). Mice with disrupted TFEB-Atp6v1h signaling exhibited impaired lysosomal acidification, reduced microglial response, and increased tau pathology (wang2024tfeb–vacuolaratpasesignaling pages 1-7). This work positioned ATP6V1H within the TFEB-V-ATPase-lysosome axis as a critical node in neuroinflammatory and neurodegenerative processes.
A 2024 study investigated Atp6v1h deficiency in a mouse model of simulated microgravity-induced bone loss (zhao2024atp6v1hdeficiencyblocks pages 1-2). Atp6v1h heterozygous knockout mice displayed bone loss due to reduced V-ATPase function but did not show aggravated bone loss under microgravity conditions (zhao2024atp6v1hdeficiencyblocks pages 1-2). Transcriptomic analysis revealed that Atp6v1h levels influence bone remodeling through the Fos-Jun-Src-Integrin pathway, affecting osteoclast activity and bone resorption (zhao2024atp6v1hdeficiencyblocks pages 1-2). These findings position ATP6V1H as a potential therapeutic target for osteoporosis and environmental bone loss.
Earlier longitudinal studies in humans reported decreased ATP6V1H mRNA expression in peripheral blood during progression from impaired fasting glucose to overt type 2 diabetes (molina2011decreasedexpressionof pages 1-3). The downregulation of ATP6V1H was statistically significant within individuals as diabetes developed, suggesting a role for V-ATPase dysfunction in diabetes-associated metabolic changes (molina2011decreasedexpressionof pages 1-3).
A 2023 review cataloged disease-associated mutations in V-ATPase subunits across different isoforms (duan2018vatpasesandosteoclasts pages 1-2). While most disease mutations have been identified in other V-ATPase subunits (particularly subunit a isoforms causing renal tubular acidosis and osteopetrosis), emerging evidence continues to link ATP6V1H dysregulation to bone density disorders and metabolic disease (duan2018vatpasesandosteoclasts pages 1-2, zhao2024atp6v1hdeficiencyblocks pages 1-2).
The functional characterization of ATP6V1H is supported by multiple experimental approaches:
V-ATPases are evolutionarily conserved from yeast to humans, sharing structural and mechanistic features with F-type ATP synthases (forgac1999structureandproperties pages 1-2, eaton2021theh+atpase(vatpase) pages 1-5). Subunit H is present across eukaryotes, though its precise sequence varies. The conservation of subunit H's coupling function across species underscores its fundamental importance in V-ATPase biology (forgac1999structureandproperties pages 1-2, toei2010regulationandisoform pages 1-2).
Current expert opinion positions V-ATPase as both a fundamental housekeeping enzyme and an emerging therapeutic target (eaton2021theh+atpase(vatpase) pages 1-5, chen2024vatpaseincancer pages 1-3). The 2021 comprehensive review by Eaton and colleagues emphasized that V-ATPases are "central players in many normal and pathophysiological processes that directly influence human health in many different and sometimes unexpected ways," including cancer, neurodegeneration, diabetes, and sensory perception (eaton2021theh+atpase(vatpase) pages 1-5).
Recent reviews highlight several key future research directions:
ATP6V1H encodes the V-type proton ATPase subunit H, a single-copy regulatory component of the V1 cytosolic domain that couples ATP hydrolysis to proton transport through the V0 membrane sector. Structurally positioned at the V1-V0 interface, subunit H stabilizes the assembled holoenzyme and influences rotational mechanics during the catalytic cycle. The V-ATPase complex acidifies endosomes, lysosomes, Golgi compartments, and secretory vesicles, and in specialized cells functions at the plasma membrane for bone resorption, renal acidification, and tumor invasion. ATP6V1H-containing V-ATPases participate in critical signaling pathways including mTORC1/AMPK nutrient sensing, TFEB-regulated lysosomal biogenesis, autophagy, and reversible assembly regulation. Recent 2023-2025 research has established ATP6V1H as a TFEB-responsive gene essential for lysosomal function in neurodegeneration, a regulator of bone homeostasis linked to osteoporosis mechanisms, and a component controlled by ATG16L1 and DMXL1-mediated assembly machinery. These findings position ATP6V1H within an expanding understanding of V-ATPase as both a fundamental proton pump and a signaling hub with broad implications for human health and disease.
References
(wang2020structuresofa pages 3-5): Longfei Wang, Di Wu, Carol V. Robinson, Hao Wu, and Tian-Min Fu. Structures of a complete human v-atpase reveal mechanisms of its assembly. Molecular Cell, 80:501-511.e3, Nov 2020. URL: https://doi.org/10.1016/j.molcel.2020.09.029, doi:10.1016/j.molcel.2020.09.029. This article has 184 citations and is from a highest quality peer-reviewed journal.
(forgac1999structureandproperties pages 1-2): Michael Forgac. Structure and properties of the vacuolar (h+)-atpases*. The Journal of Biological Chemistry, 274:12951-12954, May 1999. URL: https://doi.org/10.1074/jbc.274.19.12951, doi:10.1074/jbc.274.19.12951. This article has 417 citations.
(eaton2021theh+atpase(vatpase) pages 1-5): Amity F. Eaton, Maria Merkulova, and Dennis Brown. The h+-atpase (v-atpase): from proton pump to signaling complex in health and disease. Mar 2021. URL: https://doi.org/10.1152/ajpcell.00442.2020, doi:10.1152/ajpcell.00442.2020. This article has 188 citations.
(wang2020structuresofa pages 1-3): Longfei Wang, Di Wu, Carol V. Robinson, Hao Wu, and Tian-Min Fu. Structures of a complete human v-atpase reveal mechanisms of its assembly. Molecular Cell, 80:501-511.e3, Nov 2020. URL: https://doi.org/10.1016/j.molcel.2020.09.029, doi:10.1016/j.molcel.2020.09.029. This article has 184 citations and is from a highest quality peer-reviewed journal.
(chen2024vatpaseincancer pages 1-3): Tingting Chen, Xiaotan Lin, Shuo Lu, and Bo Li. V-atpase in cancer: mechanistic insights and therapeutic potentials. Cell Communication and Signaling : CCS, Dec 2024. URL: https://doi.org/10.1186/s12964-024-01998-9, doi:10.1186/s12964-024-01998-9. This article has 25 citations.
(toei2010regulationandisoform pages 1-2): Masashi Toei, Regina Saum, and Michael Forgac. Regulation and isoform function of the v-atpases. Biochemistry, 49 23:4715-23, Jun 2010. URL: https://doi.org/10.1021/bi100397s, doi:10.1021/bi100397s. This article has 503 citations and is from a peer-reviewed journal.
(jefferies2008functionstructureand pages 1-2): Kevin C. Jefferies, Daniel J. Cipriano, and Michael Forgac. Function, structure and regulation of the vacuolar (h+)-atpases. Archives of biochemistry and biophysics, 476 1:33-42, Aug 2008. URL: https://doi.org/10.1016/j.abb.2008.03.025, doi:10.1016/j.abb.2008.03.025. This article has 345 citations and is from a peer-reviewed journal.
(wang2020structuresofa pages 5-7): Longfei Wang, Di Wu, Carol V. Robinson, Hao Wu, and Tian-Min Fu. Structures of a complete human v-atpase reveal mechanisms of its assembly. Molecular Cell, 80:501-511.e3, Nov 2020. URL: https://doi.org/10.1016/j.molcel.2020.09.029, doi:10.1016/j.molcel.2020.09.029. This article has 184 citations and is from a highest quality peer-reviewed journal.
(eaton2021theh+atpase(vatpase) pages 5-9): Amity F. Eaton, Maria Merkulova, and Dennis Brown. The h+-atpase (v-atpase): from proton pump to signaling complex in health and disease. Mar 2021. URL: https://doi.org/10.1152/ajpcell.00442.2020, doi:10.1152/ajpcell.00442.2020. This article has 188 citations.
(duan2018vatpasesandosteoclasts pages 1-2): Xiaohong Duan, Shaoqing Yang, Lei Zhang, and Tielin Yang. V-atpases and osteoclasts: ambiguous future of v-atpases inhibitors in osteoporosis. Theranostics, 8:5379-5399, Oct 2018. URL: https://doi.org/10.7150/thno.28391, doi:10.7150/thno.28391. This article has 86 citations and is from a domain leading peer-reviewed journal.
(duque2025atg16l1controlsmammalian pages 1-3): Thabata L.A. Duque, Masroor Paddar, Einar Trosdal, Ruheena Javed, Lee Allers, Michal H. Mudd, Prithvi Akepati, Soumya R. Mishra, Michelle Salemi, Brett Phinney, Shawn B. Bratton, Thomas Wileman, and Vojo Deretic. Atg16l1 controls mammalian vacuolar proton atpase. Sep 2025. URL: https://doi.org/10.1083/jcb.202503166, doi:10.1083/jcb.202503166. This article has 2 citations and is from a highest quality peer-reviewed journal.
(wang2024tfeb–vacuolaratpasesignaling pages 1-7): Baiping Wang, Heidi Martini-Stoica, Chuangye Qi, Tzu-Chiao Lu, Shuo Wang, Wen Xiong, Yanyan Qi, Yin Xu, Marco Sardiello, Hongjie Li, and Hui Zheng. Tfeb–vacuolar atpase signaling regulates lysosomal function and microglial activation in tauopathy. Nature neuroscience, 27:48-62, Nov 2024. URL: https://doi.org/10.1038/s41593-023-01494-2, doi:10.1038/s41593-023-01494-2. This article has 81 citations and is from a highest quality peer-reviewed journal.
(zhao2024atp6v1hdeficiencyblocks pages 1-2): Zanyan Zhao, Xiangpu Wang, Yu Ma, and Xiaohong Duan. Atp6v1h deficiency blocks bone loss in simulated microgravity mice through the fos-jun-src-integrin pathway. International Journal of Molecular Sciences, 25:637, Jan 2024. URL: https://doi.org/10.3390/ijms25010637, doi:10.3390/ijms25010637. This article has 4 citations.
(lee2025dmxl1promotesrecruitment pages 1-2): Chan Lee, Matthew J. G. Eldridge, Miguel A. Gonzalez-Lozano, Thomas Bresnahan, Zachary Niday, Donato Del Camino, Tao Fu, Joao A. Paulo, Magdalene M. Moran, Sophie Helaine, and J. Wade Harper. Dmxl1 promotes recruitment of v1-atpase to lysosomes upon trpml1 activation. Nature structural & molecular biology, Jun 2025. URL: https://doi.org/10.1038/s41594-025-01581-x, doi:10.1038/s41594-025-01581-x. This article has 14 citations and is from a highest quality peer-reviewed journal.
(molina2011decreasedexpressionof pages 1-3): Melanie F. Molina, Hui-Qi Qu, Anne R. Rentfro, Saraswathy Nair, Yang Lu, Craig L. Hanis, Joseph B. McCormick, and Susan P. Fisher-Hoch. Decreased expression of atp6v1h in type 2 diabetes: a pilot report on the diabetes risk study in mexican americans. Biochemical and biophysical research communications, 412 4:728-31, Sep 2011. URL: https://doi.org/10.1016/j.bbrc.2011.08.041, doi:10.1016/j.bbrc.2011.08.041. This article has 29 citations and is from a peer-reviewed journal.